Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 6/20 | 0.41 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.40 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.38 |
| ▸ | GPR6 | P46095 | 1/20 | 0.38 |
| ▸ | MPL | P40238 | 1/20 | 0.38 |
| ▸ | WNT3A | P56704 | 2/20 | 0.37 |
| ▸ | F10 | P00742 | 1/20 | 0.37 |
| ▸ | DRD4 | P21917 | 1/20 | 0.36 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | RORC | P51449 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2222960 | 0.85 | ACKR3 (0.44) | CXCR3ALDH1A1 | |
| SCHEMBL2224894 | 0.84 | IDH2 (0.46) | CXCR3ALDH1A1 | |
| SCHEMBL2223364 | 0.84 | CXCR3 (0.53) | CXCR3 | |
| SCHEMBL2272108 | 0.84 | CXCR3 (0.42) | CXCR3 | |
| SCHEMBL2223250 | 0.84 | CACNA1I (0.45) | CXCR3ALDH1A1 | |
| SCHEMBL2224561 | 0.84 | RORC (0.39) | MALT1CXCR3GPR6F10ALDH1A1 | |
| SCHEMBL2222289 | 0.83 | F10 (0.42) | GPR6F10ALDH1A1 | |
| SCHEMBL2268312 | 0.83 | GAA (0.45) | CXCR3ALDH1A1 | |
| SCHEMBL2269849 | 0.82 | CKS1B (0.42) | CXCR3WNT3A | |
| SCHEMBL2265078 | 0.81 | ACKR3 (0.45) | CXCR3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130029971-A1 | CXCR3 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-01-31 | — | — | US | claimed |
| WO-2011084985-A1 | CXCR3 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-07-14 | — | — | WO | claimed |
| US-8952004-B2 | CXCR3 receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-02-10 | — | — | US | disclosed |
| US-8952004-B2 | CXCR3 receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-02-10 | — | — | US | disclosed |
| US-20130029971-A1 | CXCR3 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-01-31 | — | — | US | disclosed |
| US-20130029971-A1 | CXCR3 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-01-31 | — | — | US | disclosed |
| WO-2011084985-A1 | CXCR3 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-07-14 | — | — | WO | disclosed |
| WO-2011084985-A1 | CXCR3 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130029971-A1 | CXCR3 RECEPTOR ANTAGONISTS | CXCR3, CXCR1, CXCR2 | ABL1 1696/4885MALT1 1463/4885CXCR3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.